The value of screening trials

by Emmett B. Keeler


Purchase Print Copy

 FormatList Price Price
Add to Cart Paperback3 pages $20.00 $16.00 20% Web Discount

Screening trials provide information on cancer treatment which is otherwise practically impossible to obtain. Such trials are inherently expensive because of the size, but are easily justified economically by the solid information they produce. If screening proves to be efficacious, much of the expense goes into improved medical care for the participants. If screening does not improve health, then the evidence from the trial can have an impact on costs that far outweighs its expense. For example, evidence from the HIP screening trial is primarily responsible for recent NCI guidelines limiting mammograms in young women. The resultant savings in a single year are greater than the total costs of the study.

This report is part of the RAND Corporation Paper series. The paper was a product of the RAND Corporation from 1948 to 2003 that captured speeches, memorials, and derivative research, usually prepared on authors' own time and meant to be the scholarly or scientific contribution of individual authors to their professional fields. Papers were less formal than reports and did not require rigorous peer review.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.